A strain of Lactobacillus reuteri AUI2506 and its applications

Abstract

This invention provides a *Lactobacillus reuteri* AUI2506 strain and its applications. The *Lactobacillus reuteri* AUI2506 strain of this invention is a probiotic that grows rapidly, requires simple fermentation conditions, is biosafe, and exhibits good acid and bile salt tolerance, auto-aggregation ability, and surface hydrophobicity. It survives for a long time and maintains high activity in the gastrointestinal tract, contributing to positive health effects. Furthermore, this strain possesses antioxidant, anti-inflammatory, weight-loss, blood sugar-lowering, and adjunctive blood sugar-lowering effects, filling a gap in existing technologies and providing a new and effective means to improve metabolic health.

Description

Technical Field

[0001] This invention relates to biotechnology, and more particularly to a Lactobacillus reuteri AUI2506 and its applications. Background Technology

[0002] With global economic development and changing lifestyles, the incidence of metabolic diseases such as obesity and diabetes is on a continuous upward trend, becoming a serious global public health problem. These diseases not only cause serious complications such as cardiovascular and cerebrovascular diseases, kidney damage, and retinopathy, significantly reducing patients' quality of life, but also place a heavy economic burden on families and social healthcare systems. Meanwhile, an imbalance in the body's oxidative stress plays a key role in the development of obesity and diabetes. Excessive reactive oxygen species can damage cell function, exacerbate insulin resistance, and accelerate the progression of complications. Therefore, antioxidant intervention has become one of the important directions for the prevention and control of metabolic diseases.

[0003] Currently, interventions for obesity and diabetes mainly include lifestyle interventions and drug treatments. While drugs can control weight or blood sugar levels to some extent, they generally have side effects such as gastrointestinal discomfort and liver and kidney damage, and their long-term safety is questionable, making it difficult to meet patients' long-term intervention needs. Therefore, developing natural, safe, and side-effect-free functional products for weight loss, anti-oxidation, and blood sugar lowering or adjunctive blood sugar lowering has become a research hotspot in the biomedical and food fields. Summary of the Invention

[0004] The purpose of this invention is to provide a new strain of Lactobacillus reuteri with significant weight loss, antioxidant, anti-inflammatory, hypoglycemic or adjuvant hypoglycemic activities and its applications, so as to fill the gap in the existing technology and provide a new and effective means to improve metabolic health.

[0005] This invention provides a Lactobacillus reuteri AUI2506, which was deposited on March 16, 2026, at the Guangdong Provincial Center for Microbial Culture Collection, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCC NO: 67957 and classified as Limosilactobacillus reuteri.

[0006] The present invention provides a culture, fermentation product, or fermentation supernatant of the above-mentioned Lactobacillus reuteri AUI2506.

[0007] The present invention provides a microbial inoculant, comprising the above-mentioned Lactobacillus reuteri AUI2506 and / or the above-mentioned culture or fermentation product or fermentation supernatant.

[0008] This invention provides the application of the above-mentioned Lactobacillus reuteri AUI2506, the above-mentioned culture or fermentation product or fermentation supernatant, and the above-mentioned microbial agent in the preparation of products for weight loss, anti-oxidation, anti-inflammation, blood sugar reduction or auxiliary blood sugar reduction.

[0009] In the application described above, the viable count of Lactobacillus reuteri AUI2506 in the product is 1×10⁻⁶. 6 -10 10 CFU / mL or 1×10 6 -10 10 CFU / g.

[0010] In the applications described above, the product also includes a carrier and / or physiologically acceptable excipients;

[0011] The carrier includes at least one of microcapsules, microspheres, nanoparticles, and liposomes;

[0012] The excipients include at least one of the following: fillers, flavoring agents, diluents, wetting agents, binders, disintegrants, lubricants, color, flavor and aroma modifiers, solvents, solubilizers, co-solvents, emulsifiers, antioxidants, metal complexing agents, inert gases, preservatives, local analgesics, pH adjusters, and isotonic or isotropic modifiers.

[0013] As described above, the product includes at least one of food, functional food, health food, and pharmaceutical.

[0014] As described above, functional foods include at least one of the following: foods for special dietary purposes, foods for special medical purposes, infant formula, children's formula, adolescent formula, adult formula, functional powders, functional granules, functional capsules, functional beverages, and sports nutrition foods.

[0015] As described above, the health food includes at least one of the following: health foods for weight loss, anti-oxidation, anti-inflammation, and blood sugar reduction.

[0016] As described above, the drug includes at least one of the following: drugs for the prevention or treatment of hyperglycemia, drugs for the prevention or treatment of diabetes, drugs for the prevention or treatment of obesity, and drugs for the prevention or treatment of diseases caused by overweight.

[0017] This invention provides a novel *Lactobacillus reuteri* strain, AUI2506. This strain is a probiotic that grows rapidly, requires simple fermentation conditions, and is practical for large-scale industrial production. It also exhibits strong acid and bile salt resistance, spontaneous aggregation, and hydrophobic surface properties, allowing it to survive for a long time and maintain high activity in the gastrointestinal tract, thus enhancing its positive health effects. Furthermore, it demonstrates good biocompatibility, exhibiting good antibiotic resistance without causing hemolysis. In addition, this strain possesses antioxidant, anti-inflammatory, weight-loss, hypoglycemic, and adjunctive hypoglycemic effects. Therefore, this new strain fills a technological gap and provides a new and effective means to improve metabolic health. Attached Figure Description

[0018] Figure 1 This is a colony morphology diagram of AUI2506 in one embodiment of the present invention;

[0019] Figure 2 This is a morphological diagram of strain AUI2506 in one embodiment of the present invention;

[0020] Figure 3 This is a growth curve of AUI2506 in one embodiment of the present invention;

[0021] Figure 4 This is a graph showing the carbohydrate metabolism results of AUI2506 in one embodiment of the present invention;

[0022] Figure 5 This is a hemolysis result diagram of AUI2506 in one embodiment of the present invention;

[0023] Figure 6 This is a statistical chart showing the mortality rate of zebrafish juveniles in one embodiment of the present invention;

[0024] Figure 7 This is a weight chart of zebrafish juveniles in one embodiment of the present invention;

[0025] Figure 8 This is a statistical chart of blood glucose concentration in juvenile zebrafish according to one embodiment of the present invention;

[0026] Figure 9 This is a statistical chart of the inflammatory factor IL-6 in juvenile zebrafish in one embodiment of the present invention;

[0027] Figure 10 This is a statistical graph of the inflammatory factor TNF-α in zebrafish juveniles in one embodiment of the present invention;

[0028] Figure 11 This is a statistical chart of glucose tolerance in juvenile zebrafish according to one embodiment of the present invention;

[0029] Figure 12This is a statistical graph showing the area under the blood glucose concentration-time curve of zebrafish juveniles in one embodiment of the present invention. Detailed Implementation

[0030] To enable those skilled in the art to better understand the present invention, the present invention will be further described in detail below. The specific embodiments listed below are merely descriptions of the principles and features of the present invention, and the examples are only for explaining the present invention and are not intended to limit the scope of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0031] Probiotics, as a class of live microorganisms beneficial to host health, have shown broad application prospects in the prevention and control of metabolic diseases due to their beneficial properties such as regulating intestinal flora balance, improving host metabolism, and enhancing the body's immune function. However, the probiotic functions of probiotics exhibit significant strain specificity, with considerable differences in function between strains from different sources and with different genotypes. Current research on probiotics for metabolic diseases largely focuses on developing single functions. Probiotic strains possessing multiple synergistic functions such as weight loss, anti-oxidation, anti-inflammation, and blood sugar reduction or adjuvant blood sugar reduction remain relatively scarce, and the mechanisms of action of these functions are not yet fully elucidated, making it difficult to meet market demand for multifunctional metabolic regulatory products.

[0032] To address the shortcomings of existing technologies, this invention aims to develop a novel *Lactobacillus reuteri* strain with clearly defined functions of weight loss, anti-oxidation, anti-inflammation, and hypoglycemic control, and to apply it to the preparation of related functional products. This is significant for enriching the variety of functional probiotic products and meeting consumers' demand for natural health interventions. Therefore, this invention aims to provide a *Lactobacillus reuteri* strain with significant weight loss, anti-oxidation, anti-inflammation, hypoglycemic, or hypoglycemic control activities and its applications, filling a technological gap and providing a new and effective means to improve metabolic health.

[0033] The first aspect of this invention provides a Lactobacillus reuteri AUI2506, which was deposited on March 16, 2026, at the Guangdong Provincial Center for Microbial Culture Collection, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCC NO: 67957 and classified as Limosilactobacillus reuteri.

[0034] Experiments have shown that this new strain has the following advantages:

[0035] (1) Rapid growth and simple fermentation conditions:

[0036] Lactobacillus reuteri AUI2506 has high metabolic activity and strong growth ability. After being inoculated into MRS broth medium, it can quickly enter the fermentation state at 37°C, and its metabolites can accumulate in large quantities in the fermentation system. Moreover, the carbohydrates required by this strain are inexpensive and readily available, and can be D-glucose, D-lactose, D-maltose or D-sucrose.

[0037] (2) Strong resistance to acid and bile salts:

[0038] Lactobacillus reuteri AUI2506 can effectively tolerate acids, bile salts, or proteases in gastric or intestinal juices and still has good activity in the human gastrointestinal tract. Therefore, it may have good gastrointestinal survival ability, which helps it exert its probiotic effects.

[0039] (3) High security:

[0040] On the one hand, Lactobacillus reuteri AUI2506 has good antibiotic resistance, thus having high biosafety; in addition, its resistance to some clinically important antibiotics makes Lactobacillus reuteri AUI2506 an effective strain that can be used in combination with antibiotics to treat bacterial infections.

[0041] On the other hand, Lactobacillus reuteri AUI2506 is not hemolytic, meaning it does not produce hemolysin to cause red blood cell rupture and thus hemolysis.

[0042] (4) Excellent self-aggregation ability and surface hydrophobicity:

[0043] Lactobacillus reuteri AUI2506 has a high autoaggregation capacity and a hydrophobic surface, which can enhance its ability to adhere to the intestinal epithelial mucus layer, increase its survival rate and residence time in the gastrointestinal tract, thereby enabling it to exert a positive health effect.

[0044] (5) Good antioxidant capacity:

[0045] Lactobacillus reuteri AUI2506 can effectively scavenge 1,1-diphenyl-2-trinitrophenylhydrazine (DPPH) and hydroxyl radicals, thereby alleviating chronic oxidative damage or oxidative stress caused by excessive free radicals.

[0046] (6) Good ability to lower blood sugar or assist in lowering blood sugar:

[0047] Lactobacillus reuteri AUI2506 can effectively inhibit α-glucosidase and reduce blood glucose concentration.

[0048] (7) Good weight loss ability:

[0049] Lactobacillus reuteri AUI2506 can effectively reduce weight.

[0050] (8) Good anti-inflammatory ability:

[0051] Lactobacillus reuteri AUI2506 can reduce the levels of inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) in hyperglycemic organisms, thereby exerting a good anti-inflammatory effect.

[0052] (9) Good ability to alleviate glucose load:

[0053] Lactobacillus reuteri AUI2506 can significantly alleviate glucose load and improve symptoms of hyperglycemia.

[0054] In summary, the *Lactobacillus reuteri* AUI2506 provided in the first aspect of this invention is a probiotic. Firstly, it grows rapidly and requires simple fermentation conditions, thus possessing practicality and facilitating large-scale industrial production. Secondly, it exhibits strong acid and bile salt resistance, excellent auto-aggregation ability, and superior surface hydrophobicity, allowing for long survival and high activity in the gastrointestinal tract, thus enhancing its positive health effects. Thirdly, it demonstrates high safety, exhibiting good antibiotic resistance without hemolysis. Finally, it possesses excellent antioxidant, anti-inflammatory, weight-loss, hypoglycemic, and adjunctive hypoglycemic effects. Therefore, this novel *Lactobacillus reuteri* strain fills a technological gap and provides a new and effective means to improve metabolic health.

[0055] A second aspect of the present invention provides a culture, fermentation product, or fermentation supernatant of the above-mentioned Lactobacillus reuteri AUI2506.

[0056] The fermentation product of Lactobacillus reuteri AUI2506 can be a fermentation system (e.g., fermentation broth) obtained by fermenting Lactobacillus reuteri AUI2506, which includes Lactobacillus reuteri AUI2506 cells, fermentation medium and metabolites produced during fermentation.

[0057] The fermentation supernatant of Lactobacillus reuteri AUI2506 can be the supernatant liquid phase obtained after removing bacterial cells from the above fermentation material by separation methods such as centrifugation and filtration, and contains metabolic products secreted by bacterial cells.

[0058] Cultures of Lactobacillus reuteri AUI2506 may include at least one of the following: fermentation product of Lactobacillus reuteri AUI2506 and its concentrated product, extract or dried product; fermentation supernatant of Lactobacillus reuteri AUI2506 and its concentrated product, extract or dried product; spore suspension of Lactobacillus reuteri AUI2506; fermentation precipitate of Lactobacillus reuteri AUI2506; or metabolites of Lactobacillus reuteri AUI2506.

[0059] In one embodiment, the method for preparing the ferment of Lactobacillus reuteri AUI2506 includes: inoculating Lactobacillus reuteri AUI2506 into MRS broth medium at an inoculum of 1-5% (v / v) and culturing at 30-45℃ for 12-36 h to obtain the ferment of Lactobacillus reuteri AUI2506.

[0060] In one embodiment, the method for preparing fermentation supernatant of Lactobacillus reuteri AUI2506 includes: inoculating Lactobacillus reuteri AUI2506 into MRS broth medium at an inoculation rate of 1-5% (v / v), culturing at 30-45℃ for 12-36 h for activation, activating for two consecutive generations, centrifuging at 5000-7000 r / min and 2-8℃ for 5-20 min, and taking the supernatant as the fermentation supernatant of Lactobacillus reuteri AUI2506.

[0061] In one embodiment, the method for preparing fermentation broth precipitate of Lactobacillus reuteri AUI2506 includes: inoculating Lactobacillus reuteri AUI2506 into MRS broth medium at an inoculum size of 1-5% (v / v), culturing at 30-45℃ for 12-36 h for activation, activating for two consecutive generations, centrifuging at 5000-7000 r / min and 2-8℃ for 5-20 min, discarding the supernatant, and taking the precipitate and washing it with physiological saline to obtain the fermentation broth precipitate of Lactobacillus reuteri AUI2506.

[0062] A third aspect of the present invention provides a microbial inoculant, comprising the aforementioned Lactobacillus reuteri AUI2506 and / or the aforementioned culture, fermentation product, or fermentation supernatant.

[0063] Microbial preparations may include at least one of Lactobacillus reuteri AUI2506 strain, its inactivated form, culture of Lactobacillus reuteri AUI2506, fermentation product, and fermentation supernatant; in addition, they may include physiologically acceptable diluents, fillers, solvents, promoters, carriers, emulsifiers, dispersants, preservatives, thickeners, adjuvants, or any combination thereof.

[0064] Lactobacillus reuteri AUI2506 can exist as a live bacterium in a microbial agent in the form of a bacterial suspension, or as an inactivated bacterial cell in a microbial agent in the form of an inactivated bacterial suspension, or as a freeze-dried powder prepared from a bacterial suspension or inactivated bacterial suspension.

[0065] In one embodiment, the method for preparing a bacterial suspension of Lactobacillus reuteri AUI2506 includes: inoculating Lactobacillus reuteri AUI2506 into MRS broth medium at an inoculation rate of 1-5% (v / v), culturing at 30-45℃ for 12-36 h for activation, activating for two consecutive generations, centrifuging at 5000-7000 r / min and 2-8℃ for 5-20 min, discarding the supernatant, washing the precipitate with physiological saline and resuspending it to obtain a bacterial suspension of Lactobacillus reuteri AUI2506.

[0066] In one embodiment, the method for preparing an inactivated bacterial suspension of Lactobacillus reuteri AUI2506 includes: inoculating Lactobacillus reuteri AUI2506 into MRS broth medium at an inoculation rate of 1-5% (v / v), culturing at 30-45℃ for 12-36 h for activation, activating for two consecutive generations, centrifuging at 5000-7000 r / min and 2-8℃ for 5-20 min, discarding the supernatant, washing the precipitate with physiological saline and resuspending it, and placing the bacterial suspension in a water bath at 60-80℃ for heat inactivation for 30-50 min to obtain an inactivated bacterial suspension of Lactobacillus reuteri AUI2506.

[0067] The fourth aspect of the present invention provides the application of the above-mentioned Lactobacillus reuteri AUI2506, the above-mentioned culture or fermentation product or fermentation supernatant, and the above-mentioned microbial agent in the preparation of products for weight loss, anti-oxidation, anti-inflammation, hypoglycemia reduction or adjuvant hypoglycemia reduction.

[0068] The *Lactobacillus reuteri* AUI2506 strain of this invention, along with its culture, fermentation product, fermentation supernatant, and microbial inoculant, holds significant value in the preparation of weight-loss, antioxidant, anti-inflammatory, hypoglycemic, or hypoglycemic adjuvant products. This strain combines multiple health benefits with rapid growth, acid and bile salt tolerance, and high safety, filling a technological gap, reducing industrial production costs, and enabling the development of multifunctional products. Its natural safety and lack of side effects provide novel solutions to metabolic-related health problems, meeting market demands for natural, safe, and multifunctional products, and possessing multifaceted significance in terms of technology, industry, health, and the market.

[0069] In one specific implementation, the viable count of Lactobacillus reuteri AUI2506 in the product is 1×10⁻⁶. 6 -10 10 CFU / mL or 1×10 6 -10 10 CFU / g has better effects on weight loss, anti-oxidation, anti-inflammation, lowering blood sugar, or assisting in lowering blood sugar. For example, the live bacteria count can be 1×10⁻⁶. 6 CFU / mL, 1×10 7 CFU / mL, 1×10 8CFU / mL, 1×10 9 CFU / mL, 1×10 10 CFU / mL and any value between any two of the above ranges; viable count can also be 1×10⁻⁶. 6 CFU / g, 1×10 7 CFU / g, 1×10 8 CFU / g, 1×10 9 CFU / g, 1×10 10 CFU / g and any value between any two of the above ranges.

[0070] Furthermore, the product also includes a carrier and / or physiologically acceptable excipients; further, the carrier includes at least one of microcapsules, microspheres, nanoparticles, and liposomes; the excipients include at least one of fillers, flavoring agents, diluents, wetting agents, binders, disintegrants, lubricants, color, flavor and aroma modifiers, solvents, solubilizers, co-solvents, emulsifiers, antioxidants, metal complexing agents, inert gases, preservatives, local analgesics, pH adjusters, and isotonic or isotropic modifiers.

[0071] In one specific implementation, the product includes at least one of food, functional food, health food, and medicine.

[0072] Among them, food can include at least one of snacks, complementary foods, food additives, dietary supplements, and nutritional fortifiers.

[0073] Functional foods may include at least one of the following: foods for special dietary purposes, foods for special medical purposes, infant formula, children's formula, adolescent formula, adult formula, functional powders, functional granules, functional capsules, functional beverages, and sports nutrition foods.

[0074] Health foods may include at least one of the following: those for weight loss, anti-oxidation, and blood sugar reduction.

[0075] The medication may include at least one of the following: medication for the prevention or treatment of hyperglycemia, diabetes, obesity, or diseases caused by overweight.

[0076] The technical solution of this application will be further explained below with reference to specific embodiments. Experimental methods in the following embodiments that do not specify specific conditions are generally performed under conventional conditions or as recommended by the manufacturer. Unless otherwise specified, all reagents used are commercially available or obtained through public channels.

[0077] Example 1: Sample Preparation

[0078] (1) Lactobacillus reuteri AUI2506:

[0079] This embodiment provides an isolated Lactobacillus reuteri AUI2506, with the following accession information: Accession number: GDMCC NO: 67957; Classification name: Lactobacillus reuteri; Accession date: March 16, 2026; Accession institution: Guangdong Provincial Center for Microbial Culture Collection; Accession institution address: 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou.

[0080] (2) Fermentation supernatant of Lactobacillus reuteri AUI2506:

[0081] This embodiment provides a method for preparing fermentation supernatant of Lactobacillus reuteri AUI2506, comprising: inoculating Lactobacillus reuteri AUI2506, which is frozen at -80℃ using the glycerol preservation method, into MRS broth medium at an inoculation rate of 2% (v / v), culturing at 37℃ for 24 h, activating for two consecutive generations, centrifuging at 6000 r / min and 4℃ for 10 min, and filtering the supernatant through a 0.22 mm aqueous microfiltration membrane to obtain fermentation supernatant of Lactobacillus reuteri AUI2506.

[0082] (3) Bacterial suspension of Lactobacillus reuteri AUI2506:

[0083] This embodiment provides a method for preparing a bacterial suspension of *Lactobacillus reuteri* AUI2506, comprising: inoculating *Lactobacillus reuteri* AUI2506, which has been frozen at -80℃ using the glycerol preservation method, into MRS broth medium at an inoculation rate of 2% (v / v), culturing at 37℃ for 24 h, activating for two consecutive generations, centrifuging at 6000 r / min and 4℃ for 10 min, discarding the supernatant, washing the precipitate three times with 0.85% physiological saline, resuspending it, and then adjusting the OD with 0.85% physiological saline. 600nm The concentration was 0.5, and the density of the bacterial suspension was 1×10⁻⁶. 8 A bacterial suspension of Lactobacillus reuteri AUI2506 was obtained by dispersing cfu / mL.

[0084] (4) Inactivated bacterial suspension of Lactobacillus reuteri AUI2506:

[0085] This embodiment provides a method for preparing an inactivated bacterial suspension of Lactobacillus reuteri AUI2506, comprising: inoculating Lactobacillus reuteri AUI2506, which has been frozen at -80℃ using the glycerol preservation method, into MRS broth medium at an inoculation rate of 2% (v / v), culturing at 37℃ for 24 h, activating for two consecutive generations, centrifuging at 6000 r / min and 4℃ for 10 min, discarding the supernatant, washing the precipitate three times with 0.85% physiological saline, resuspending it, and then adjusting the OD with 0.85% physiological saline. 600nm The concentration was 0.5, and the density of the bacterial suspension was 1×10⁻⁶. 8 The cfu / mL concentration was used to heat-inactivate the bacterial suspension in a 65℃ water bath for 40 min, resulting in an inactivated bacterial suspension of Lactobacillus reuteri AUI2506.

[0086] (5) Fermentation supernatant, bacterial suspension and inactivated bacterial suspension of LGG probiotics:

[0087] This embodiment provides a method for preparing fermentation supernatant, bacterial suspension and inactivated bacterial suspension of LGG probiotic (Lactobacillus rhamnosus GG strain), which can be referred to in Example 1 (2)-(4).

[0088] (6) A bacterial suspension of Staphylococcus aureus ATCC 25923:

[0089] This embodiment provides a method for preparing a bacterial suspension of Staphylococcus aureus ATCC 25923, which can be referred to in Example 1 (3), except that the MRS broth medium is replaced with LB liquid medium.

[0090] Example 2: Strain Identification

[0091] (1) Morphological identification:

[0092] A suspension of *Lactobacillus reuteri* AUI2506 was inoculated into sterile MRS broth at a 2% (v / v) inoculation rate and incubated at 37°C for 24 h. The culture was then serially diluted with sterile phosphate-buffered saline (PBS) (pH 7.0), and each diluted solution was plated onto sterile MRS solid medium and incubated at 37°C for 48 h. Colony morphology was observed. (See attached image for details.) Figure 1 Select a small number of bacterial strains, stain them according to the instructions in the Gram staining kit, and then observe the individual morphology of the strains under an oil immersion microscope. See the attached image for details. Figure 2 .

[0093] The experimental results showed that after 48 hours of cultivation, round colonies formed, which were milky white, smooth and moist, with neat edges, and soft and easily picked up. Under a microscope, the strain stained purple with Gram stain, indicating it was a Gram-positive bacterium, and the strain was rod-shaped and without flagella. These results are consistent with the morphological characteristics of *Lactobacillus reuteri*.

[0094] (2) Identification of 16S rDNA gene:

[0095] The 16S rDNA gene identification was conducted by Beijing Aoke Dingsheng Biotechnology Co., Ltd. The sequencing results of Lactobacillus reuteri AUI2506 were compared with the NCBI gene database of the National Center for Biotechnology Information in the United States to obtain the identification results of the species relationship of the strain, as shown in Table 1.

[0096] Table 1

[0097]

[0098] The experimental results showed that Lactobacillus reuteri AUI2506 and Lactobacillus reuteri had a homology of 99.8%, indicating that they belong to Lactobacillus reuteri.

[0099] (3) Growth rate measurement:

[0100] A suspension of *Lactobacillus reuteri* AUI2506 was inoculated into sterile MRS broth at a 2% (v / v) inoculation rate and incubated at 37°C. During the incubation period, OD values ​​were measured every 1 hour using a microplate reader. 600nm The growth rate of the strain was measured in triplicate, and the OD values ​​obtained were used. 600nm The values ​​were used to plot the growth curve, and the results are visible. Figure 3 .

[0101] Experimental results showed that, with the increase of time, Lactobacillus reuteri AUI2506 did not have a significant lag phase and had a short latency period, indicating that Lactobacillus reuteri AUI2506 has rapid metabolic activity and strong growth ability in MRS broth medium, and can quickly enter the fermentation state. The metabolites of Lactobacillus reuteri AUI2506 accumulated in large quantities in the fermentation system.

[0102] (4) Study on carbohydrate metabolism characteristics:

[0103] Microorganisms vary in their carbohydrate metabolism capabilities and require different nutrients. Therefore, a carbohydrate identification strip (API 50 CH) was used to study carbohydrate metabolism characteristics. This strip contains 49 carbon sources that can be detected. The determination of carbohydrate metabolism was then made in conjunction with factors such as price and edibility. The specific steps are as follows:

[0104] A suspension of *Lactobacillus reuteri* AUI2506 was diluted and inoculated into sterile MRS solid medium. The culture was anaerobic at 37°C for 24 h. The bacterial strain was collected from the MRS solid medium using cotton swabs and a bacterial suspension was prepared. This suspension was then added to the wells of an API 50 CH test strip using a sterile pipette. The strips were incubated for 24 h and 48 h before being read a second time. (See details...) Figure 4 And Table 2.

[0105] Table 2

[0106]

[0107] Experimental results show that the optimal carbon source for Lactobacillus reuteri AUI2506 can be selected from D-ribose, D-xylose, D-glucose, D-fructose, D-mannose, L-sorbose, amygdalin, D-cellobiose, D-maltose, D-lactose, D-sucrose, D-trehalose, starch, or D-fucose.

[0108] Example 3: Safety evaluation of the strain

[0109] (1) Simulated gastrointestinal fluid tolerance test:

[0110] The environment of the human gastrointestinal tract can disrupt the integrity of bacterial cells, effectively preventing bacteria from entering the body and maintaining their activity. The pH in the stomach is generally between 2.5 and 3.5, while food remains in the stomach for 2-4 hours. The intestines are another barrier for probiotics to enter the human body, containing bile salts and trypsin at a concentration of 0.15-0.30% (m / v), with a stable pH of around 8.0; meanwhile, food typically transits through the intestines for 1-4 hours. Therefore, for probiotics to exert their beneficial functions in the human body, they must be tolerant to the above conditions and maintain good activity in the human gastrointestinal tract. To investigate the tolerance of *Lactobacillus reuteri* AUI2506 in simulated gastric or intestinal fluids, the following experiment was conducted:

[0111] Pepsin was dissolved in PBS to a final concentration of 0.3% (m / v), and the pH was adjusted to 3.0 with 1 mol / L hydrochloric acid (HCl) solution. The solution was then filtered through a 0.22 μm aqueous microfiltration membrane to obtain sterile simulated gastric fluid. 1.0 mL of a suspension of *Lactobacillus reuteri* AUI2506 or a suspension of LGG probiotics was inoculated into 9 mL of simulated gastric fluid. After mixing, the mixture was incubated at 37°C for 3 h. The viable cell counts at 0 h and 3 h were recorded using the dilution plating method, as detailed in Table 3.

[0112] Trypsin and bovine bile salts were dissolved in PBS to final concentrations of 0.1% (m / v) and 0.3% (m / v), respectively. The pH was adjusted to 8.0 with 1 mol / L sodium hydroxide (NaOH), and then filtered through a 0.22 μm aqueous microfiltration membrane to obtain sterile simulated intestinal fluid. 1.0 mL of a suspension of *Lactobacillus reuteri* AUI2506 or a suspension of LGG probiotics was inoculated into 9 mL of simulated intestinal fluid, mixed, and incubated at 37°C for 3 h. The viable cell counts at 0 h and 3 h were recorded using the dilution plating method, as detailed in Table 4.

[0113] In Tables 3 and 4, the survival rate is calculated using the following formula: N1 / N0 × 100%, where N1 is the number of viable bacteria after 3 hours and N0 is the number of viable bacteria after 0 hours; different letters in the same column represent significant differences (p < 0.05).

[0114] Table 3

[0115]

[0116] Table 4

[0117]

[0118] The experimental results showed that the survival rate of Lactobacillus reuteri AUI2506 in simulated gastric fluid was significantly higher than that of strain LGG (p<0.05). The survival rate of Lactobacillus reuteri AUI2506 in simulated intestinal fluid remained at a high level and was higher than that of strain LGG, showing good acid and bile salt resistance.

[0119] (2) Drug sensitivity test:

[0120] Antibiotic resistance is a crucial safety indicator for probiotics, as the transfer of resistance genes to pathogenic bacteria can threaten the host's safety. Therefore, to investigate the drug susceptibility of *Lactobacillus reuteri* AUI2506, the following experiment was conducted:

[0121] Staphylococcus aureus ATCC 25923 was used as the quality control strain, and LGG probiotics were used as the control strain. 100 μL of Lactobacillus reuteri AUI2506 bacterial suspension was evenly spread on MRS solid medium. Antimicrobial susceptibility test strips were placed on the surface of the MRS solid medium, with 3 strips evenly spaced on each petri dish. After incubation at 37°C for 48 h, the diameter of the inhibition zone was measured and recorded. Antimicrobial susceptibility was determined according to the instructions of the antimicrobial susceptibility test strips (see Table 5). The specific results are shown in Table 6.

[0122] Table 5

[0123]

[0124] Table 6

[0125]

[0126] Experimental results showed that *Lactobacillus reuteri* AUI2506 was sensitive to most antibiotics and had a high safety profile. Furthermore, its resistance to some clinically important antibiotics allows *Lactobacillus reuteri* AUI2506 to be used as an effective strain in combination with antibiotics to treat bacterial infections.

[0127] (3) Hemolytic test:

[0128] Hemolysis is an important indicator for assessing the safety of bacterial strains. Pathogenic bacteria produce hemolysin during their growth, leading to the rupture of red blood cells and resulting in hemolysis. Therefore, to investigate the hemolytic activity of *Lactobacillus reuteri* AUI2506, the following experiment was conducted:

[0129] Staphylococcus aureus ATCC 25923 was used as the quality control strain, and LGG probiotics were used as the control strain. A suspension of Lactobacillus reuteri AUI2506 was streaked onto Columbia blood agar plates and incubated upside down at 37°C for 48 h. Color changes around individual colonies were then observed. A grass-green ring around a single colony indicated α-hemolysis, a clear ring indicated β-hemolysis, and no color change indicated γ-hemolysis (i.e., no hemolysis). Specific results can be found in [link to results]. Figure 5 In the results, A represents the quality control bacteria result, B represents the Lactobacillus reuteri AUI2506 result, and C represents the LGG probiotic result.

[0130] Experimental results showed that the hemolysis result of Lactobacillus reuteri AUI2506 was γ hemolysis (i.e., non-hemolysis).

[0131] Example 4: Evaluation of the strain's auto-aggregation ability and surface hydrophobicity

[0132] The autoaggregation ability of bacterial strains refers to the phenomenon where bacteria multiply rapidly and massively during culture, causing them to spontaneously aggregate into clusters. The surface hydrophobicity of bacterial strains refers to the unstable state of the strain in polar water, leading to a series of redistribution and arrangement changes in the bacterial cells. The autoaggregation ability and surface hydrophobicity of bacterial strains are related to various adhesion phenomena, and the ability to adhere to the intestinal epithelial mucus layer is one of the main criteria for selecting probiotics: the autoaggregation ability of probiotics can increase their survival rate and residence time in the gastrointestinal tract, thereby exerting a positive health effect; the surface hydrophobicity of probiotics is often determined by assessing their affinity for hydrocarbon solvents. Generally, the higher the adhesion of probiotics to hydrocarbons, the higher the hydrophobicity and the stronger the adhesion ability. The hydrophobicity of bacterial strains can be divided into three categories: strongly hydrophobic (>50%), moderately hydrophobic (20%-50%), and hydrophilic (<20%). The strength of hydrophobicity mainly depends on the expression of polysaccharides and proteins on the cell surface.

[0133] (1) Evaluation of automatic aggregation capability:

[0134] LGG probiotics were used as the control strain. The OD 600 nm of the Lactobacillus reuteri AUI2506 bacterial suspension was adjusted to 1.00. 3 mL of the bacterial suspension was vortexed for 10 s and incubated at 37℃ for 0 h and 2 h. The absorbance of the upper layer solution at 600 nm was measured, as detailed in Table 7. The formula for calculating the autoaggregation ability (%) is as follows: (A0-A1) / A0×100%, where A0 is the absorbance value measured after 0 h of incubation and A1 is the absorbance value measured after 2 h of incubation. Different letters in the same column represent significant differences (p<0.05).

[0135] (2) Evaluation of surface hydrophobicity:

[0136] LGG probiotics were used as the control strain. The OD 600 nm of the *Lactobacillus reuteri* AUI2506 bacterial suspension was adjusted to 1.00. 3 mL of the suspension was mixed with 1 mL of xylene, vortexed for 2 min, and then allowed to stand at room temperature for 15 min. Layering occurred, and the aqueous phase was carefully sampled. The OD value of the aqueous phase was measured at 600 nm. Details are shown in Table 6. The formula for calculating surface hydrophobicity (%) is as follows: (B0-B1) / B0×100%, where B0 is the initial absorbance value (i.e., OD). 600nm =1.00), B1 is the absorbance value of the aqueous phase; different letters in the same column represent significant differences (p<0.05).

[0137] Table 7

[0138]

[0139] The experimental results showed that the autoaggregation ability and surface hydrophobicity of Lactobacillus reuteri AUI2506 were significantly higher than those of LGG probiotics (p<0.05), demonstrating good autoaggregation ability and surface hydrophobicity, indicating that Lactobacillus reuteri AUI2506 may have good adhesion ability to the intestinal epithelial mucus layer.

[0140] Example 5: Evaluation of the antioxidant properties of the strain

[0141] (1) Ability to remove DPPH

[0142] 1,1-Diphenyl-2-trinitrophenylhydrazine (DPPH) is a synthetically produced stable free radical. Its contained electronic domains give it a deep purple color, and it has a maximum absorption peak at 517 nm. Antioxidants have the ability to capture and neutralize free radicals and can react with DPPH, leading to a decrease in the absorbance of DPPH-containing solutions. Therefore, to investigate the ability of *Lactobacillus reuteri* AUI2506 to scavenge DPPH, the following experiment was conducted:

[0143] LGG probiotics were used as the control strain. 4 mg of DPPH was accurately weighed, dissolved in anhydrous ethanol, and diluted to a final volume of 50 mL in a volumetric flask to obtain a 0.2 mmol / L DPPH anhydrous ethanol solution. This solution was stored at 0-4℃ in the dark and used immediately after preparation. 2 mL of the DPPH anhydrous ethanol solution was mixed with 2 mL of fermentation supernatant, bacterial suspension, or inactivated bacterial suspension of *Lactobacillus reuteri* AUI2506. 2 mL of distilled water was then mixed with 2 mL of the DPPH anhydrous ethanol solution. The mixture was reacted in the dark for 30 min, and the absorbance was measured at 517 nm. Three parallel experiments were conducted. Details are shown in Table 8. The formula for calculating the DPPH free radical scavenging rate (%) is as follows:

[0144]

[0145] Cr represents the absorbance value of the mixture of DPPH anhydrous ethanol solution and fermentation supernatant, bacterial suspension or inactivated bacterial suspension of Lactobacillus reuteri AUI2506; Cs represents the absorbance value of the mixture of anhydrous ethanol solution and fermentation supernatant, bacterial suspension or inactivated bacterial suspension of Lactobacillus reuteri AUI2506; Ct represents the absorbance value of the mixture of distilled water and DPPH anhydrous ethanol solution; different letters in the same column indicate significant differences (p < 0.05).

[0146] Table 8

[0147]

[0148] The experimental results showed that the DPPH scavenging rates of fermentation supernatant, bacterial suspension and inactivated bacterial suspension of Lactobacillus reuteri AUI2506 were significantly higher than those of LGG probiotics (p<0.05), indicating that Lactobacillus reuteri AUI2506 has strong in vitro antioxidant capacity.

[0149] (2) Ability to scavenge hydroxyl radicals:

[0150] The ability of a bacterial strain to scavenge hydroxyl radicals is an important indicator of its antioxidant activity. Hydroxyl radicals are a type of free radical; while free radicals at normal concentrations have physiological functions, excessive amounts can lead to chronic oxidative damage. Excessive free radicals can damage nucleic acids, lipids, proteins, polyunsaturated fatty acids, and carbohydrates, ultimately causing cell dysfunction and even death. Furthermore, hydroxyl radicals can induce lipid peroxidation, exacerbating oxidative stress. Therefore, to investigate the ability of *Lactobacillus reuteri* AUI2506 to scavenge hydroxyl radicals, the following experiment was conducted:

[0151] LGG probiotics were used as the control strain. 40 μL of 2.5 mmol / L o-phenanthroline was added to 0.02 mol / L PBS (pH 7.4), 40 μL of fermentation supernatant, bacterial suspension, or inactivated bacterial suspension of *Lactobacillus reuteri* AUI2506. After sufficient reaction, 40 μL of 2.5 mmol / L ferrous sulfate was added and mixed thoroughly. Then, 40 μL of 20 mmol / L hydrogen peroxide was added. The mixture was incubated at 37°C for 1.5 h, and the absorbance (Ds) was measured at 536 nm. Three parallel experiments were set up, as detailed in Table 9. The formula for calculating the hydroxyl radical scavenging rate (%) is as follows:

[0152]

[0153] In the formula, Db is prepared in the same way as Ds, except that distilled water is used instead of hydrogen peroxide, and distilled water is used instead of the fermentation supernatant, bacterial suspension or inactivated bacterial suspension of Lactobacillus reuteri AUI2506; D0 is prepared in the same way as Ds, except that distilled water is used instead of the fermentation supernatant, bacterial suspension or inactivated bacterial suspension of Lactobacillus reuteri AUI2506; different letters in the same column represent significant differences (p < 0.05), and ns indicates no significant difference.

[0154] Table 9

[0155]

[0156] The experimental results showed that the hydroxyl radical scavenging capacity of the fermentation supernatant and bacterial suspension of Lactobacillus reuteri AUI2506 was significantly higher than that of LGG probiotics (p<0.05). The hydroxyl radical scavenging capacity of the inactivated bacterial suspension was not significantly different from that of LGG probiotics, but the effect was better than that of LGG probiotics, indicating that it has a strong in vitro antioxidant capacity.

[0157] Example 6: Evaluation of the inhibition rate of the strain against α-glucosidase

[0158] α-Glucosidase inhibition rate refers to the degree to which the sample inhibits the catalytic activity of α-glucosidase, expressed as a percentage (%). α-Glucosidase is responsible for hydrolyzing intestinal carbohydrates (such as starch and sucrose) into glucose. Therefore, inhibiting the activity of this enzyme can delay glucose absorption and reduce postprandial blood glucose peaks, making it a key in vitro indicator for screening probiotics with hypoglycemic or hypoglycemic-adjuvant effects. To investigate the α-glucosidase inhibition rate of *Lactobacillus reuteri* AUI2506, the following experiment was conducted:

[0159] Acarbose (0.001 M) was used as the drug control group, and LGG probiotics were used as the strain control. A 96-well microtiter plate was prepared, and 25 μL of 2.5 mmol / L nitrophenyl-β-D-glucopyranoside (PNPG) solution and 25 μL of fermentation supernatant, bacterial suspension, or inactivated bacterial suspension of *Lactobacillus reuteri* AUI2506 were added to the reaction wells. The plate was incubated at 37°C for 10 min. Then, 50 μL of 0.2 U / μL α-glucosidase solution was added, and the reaction was continued at 37°C for 15 min. Finally, 100 μL of 0.2 mol / L sodium carbonate (Na2CO3) solution was quickly added to terminate the reaction. The absorbance (E) was measured at 405 nm using a microplate reader. Three parallel experiments were conducted. Details are shown in Table 10. The formula for calculating the α-glucosidase inhibition rate (%) is as follows:

[0160]

[0161] In the formula, F can be prepared in the same way as E, except that PBS (pH 6.8) is used instead of α-glucosidase solution; G can be prepared in the same way as E, except that PBS (pH 6.8) is used instead of fermentation supernatant, bacterial suspension or inactivated bacterial suspension of Lactobacillus reuteri AUI2506; H can be prepared in the same way as E, except that PBS (pH 6.8) is used instead of α-glucosidase solution, and PBS (pH 6.8) is used instead of fermentation supernatant, bacterial suspension or inactivated bacterial suspension of Lactobacillus reuteri AUI2506; different letters in the same column represent significant differences (p < 0.05).

[0162] Table 10

[0163]

[0164] The experimental results showed that the fermentation supernatant of Lactobacillus reuteri AUI2506 had a significantly higher inhibition rate of α-glucosidase than LGG probiotics and the hypoglycemic drug acarbose. The inhibition rates of both the bacterial suspension and the inactivated bacterial suspension of Lactobacillus reuteri AUI2506 on α-glucosidase were comparable to those of the hypoglycemic drug acarbose, and both were superior to those of the LGG strain. This indicates that Lactobacillus reuteri AUI2506 has a strong ability to inhibit α-glucosidase.

[0165] Example 7: Evaluation of the hypoglycemic effect of the strain on a zebrafish hyperglycemia model

[0166] (1) Construction of a zebrafish hyperglycemia model:

[0167] Eight tanks of sexually mature wild-type zebrafish were naturally paired for breeding. The resulting eggs were disinfected, and 300 mL of embryo culture medium was added to the fry hatching tank, with the medium changed every 24 hours. Well-developed and highly active fry, 5 days post-fertilization (5 dpf), were randomly selected and placed in newly opened 6-well plates, with 30 fry per well. The fry were divided into a blank group, a model group, a positive control group, and an AUI2506 group, with the time, date, and group clearly marked. The experimental grouping and intervention methods are shown in Table 11. The intervention period was 5 days, and each group was fed algae feed normally at 9:00 AM daily.

[0168] Table 11

[0169]

[0170] Zebrafish with a growth factor of 10 dpf were treated with the drug for 4 h from 10:30 to 14:30. After the intervention, blood glucose was measured. The glucose concentration in the tissue fluid of the zebrafish in the model group was significantly higher than that in the blank group (P < 0.001), which indicates that the zebrafish hyperglycemia model was successfully constructed.

[0171] (2) Mortality rate:

[0172] During the zebrafish model construction, the number of dead fish was counted every day at 9:00 AM. After the count, the dead fish were removed. The mortality rate statistics of zebrafish juveniles can be seen in the graph. Figure 6 .

[0173] The experimental results showed that the mortality rate of zebrafish juveniles in all groups was normal, indicating that Lactobacillus reuteri AUI2506 has good biosafety and does not cause significant damage to zebrafish.

[0174] (3) Weight:

[0175] The successfully constructed zebrafish model was washed three times with distilled water, and then three times with PBS. After washing, the PBS in the centrifuge tubes was thoroughly removed using 200 μL and 10 μL pipettes, and then the water was thoroughly absorbed using filter paper strips. The centrifuge tubes were weighed on a 0.01% balance, and the weight of the zebrafish fry was obtained by subtracting the weight of the empty centrifuge tube from the measured value. The weight statistics of the zebrafish fry can be seen in the graph. Figure 7 .

[0176] The experimental results showed that the weight of the blank group was significantly lower than that of the model group (p<0.001), and the weight of the positive control group and the AUI2506 group was significantly lower than that of the model group (p<0.05). This indicates that Lactobacillus reuteri AUI2506 can produce a good weight loss effect by lowering blood sugar or assisting in lowering blood sugar, and the effect is similar to that of the positive control metformin.

[0177] (4) Blood glucose concentration:

[0178] Add 20 μL of PBS to centrifuge tubes containing weighed zebrafish larvae, add one magnetic bead to each tube, and grind thoroughly at 50 Hz for 300 s. Centrifuge at 12000 rpm for 3 min. The supernatant is the tissue fluid of the zebrafish larvae. Immediately pipette 2 µL of the tissue fluid onto a blood glucose test strip to obtain the blood glucose concentration of the zebrafish larvae. The blood glucose concentration statistics of the zebrafish larvae can be seen in the graph. Figure 8 .

[0179] The experimental results showed that the blood glucose concentration in the blank group was 0.91 mmol / L, the blood glucose concentration in the model group was 2.63 mmol / L, the blood glucose concentration in the positive control group was 1.25 mmol / L, and the blood glucose concentration in the AUI2506 group was 1.31 mmol / L. Compared with the blank group, the blood glucose concentration in the model group increased significantly (P < 0.001), indicating that the zebrafish model was successfully established. Compared with the model group, the blood glucose concentration in the positive control group decreased significantly (P < 0.001), with a hypoglycemic efficacy of 52.47%, indicating that metformin has a significant hypoglycemic or adjunctive hypoglycemic effect on hyperglycemic zebrafish juveniles under the experimental concentration conditions. Compared with the model group, the blood glucose concentration in the AUI2506 group decreased significantly (P < 0.001), with a hypoglycemic efficacy of 50.19%, indicating that the bacterial suspension of Lactobacillus reuteri AUI2506 exhibited excellent hypoglycemic activity under the experimental concentration conditions, and its effect was comparable to that of the positive control drug metformin (52.47%).

[0180] (5) Inflammatory cytokines:

[0181] The levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in the tissue fluid of the above-mentioned zebrafish juveniles were detected using a commercially available ELISA kit (relative expression levels divided by the internal reference actin). For details, please refer to [link to kit]. Figure 9 and Figure 10 .

[0182] The experimental results showed that the levels of IL-6 and TNF-α in the model group were significantly different from those in the blank group (P < 0.001); compared with the model group, the levels of IL-6 and TNF-α in the AUI2506 group were significantly different (P < 0.01), indicating that the AUI2506 group has a certain effect on alleviating inflammation in hyperglycemic zebrafish.

[0183] (6) OGTT & AUC glucose :

[0184] An oral glucose tolerance test (OGTT) was conducted on zebrafish with a blood glucose level of 10 dpf at 10:30. Blood glucose levels were measured at 0, 1, 2, 3, and 4 hours. Blood glucose change curves were plotted, and the area under the blood glucose concentration-time curve (AUC) was calculated to explore the feasibility and stability of the blood glucose model. (See details...) Figure 11 and Figure 12 .

[0185] Figure 11 The results showed that within 4 hours after intervention, the blood glucose levels of all zebrafish juveniles in each group showed a trend of first rising and then falling. Figure 12 The results showed that the AUC value of the AUI2506 group was significantly lower than that of the model group (P < 0.001), specifically 11.54. Based on the OGTT test results and the AUC value, it can be concluded that strain AUI2506 can significantly alleviate the glucose load in hyperglycemic zebrafish and improve their symptoms.

[0186] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. Lactobacillus reuteri AUI2506, characterized in that, The Lactobacillus reuteri AUI2506 was deposited on March 16, 2026, at the Guangdong Provincial Center for Microbial Culture Collection, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCC NO: 67957 and classified as Limosilactobacillus reuteri.

2. A culture, fermentation product, or fermentation supernatant of Lactobacillus reuteri AUI2506 as described in claim 1.

3. A microbial inoculant, characterized in that, Includes Lactobacillus reuteri AUI2506 as described in claim 1 and / or the culture, fermentation product, or fermentation supernatant as described in claim 2.

4. The use of Lactobacillus reuteri AUI2506 as described in claim 1, the culture or fermentation product or fermentation supernatant as described in claim 2, and the microbial agent as described in claim 3 in the preparation of products that help with weight loss, anti-oxidation, anti-inflammation, blood sugar reduction, or blood sugar reduction.

5. Use according to claim 4, characterized in that, The number of viable cells of the Lactobacillus reuteri AUI2506 in the product is 1 x 10 6 -10 10 CFU / mL or 1 x 10 6 -10 10 CFU / g.

6. Use according to claim 4 or 5, characterized in that, The product also includes a carrier and / or physiologically acceptable excipients; The carrier includes at least one of microcapsules, microspheres, nanoparticles, and liposomes; The excipients include at least one of the following: fillers, flavoring agents, diluents, wetting agents, binders, disintegrants, lubricants, color, flavor and aroma modifiers, solvents, solubilizers, co-solvents, emulsifiers, antioxidants, metal complexing agents, inert gases, preservatives, local analgesics, pH adjusters, and isotonic or isotropic modifiers.

7. Use according to claim 4 or 5, characterized in that, The products include at least one of the following: food, functional food, health food, and medicine.

8. Use according to claim 7, characterized in that, The functional foods include at least one of the following: special dietary foods, special medical purpose foods, infant formula milk powder, children's formula milk powder, adolescent formula milk powder, adult formula milk powder, functional powders, functional granules, functional capsules, functional beverages, and sports nutrition foods.

9. Use according to claim 7, characterized in that, The health food products include at least one of the following: those that help with weight loss, anti-oxidation, anti-inflammation, and blood sugar reduction.

10. Use according to claim 7, characterized in that, The drug includes at least one of the following: drugs for the prevention or treatment of hyperglycemia, drugs for the prevention or treatment of diabetes, drugs for the prevention or treatment of obesity, and drugs for the prevention or treatment of diseases caused by overweight.

Images